Journal: medRxiv
Article Title: Translational PBPK-QSP modeling platform for antibody-drug conjugates (ADC): within-target and cross-pathway validation to bridge preclinical and clinical results
doi: 10.64898/2026.01.30.26345218
Figure Lengend Snippet: The procedures for within-target validation (left side) and cross-pathway validation (right side) of the platform PBPK-QSP model originally developed for T-DM1. AD: Aggregate data; IPD: Individual patient data; mAb: monoclonal antibody; NHP: Non-human primates; PD: pharmacodynamics; PFS: progression-free survival; PK: pharmacokinetics; SAR408701: Tusamitamab ravtansine; (T-)Dxd: trastuzumab deruxtran;; : In vitro cell culture experiment; : In vivo mouse experiment; : In vivo NHP experiment; : Clinical trial data.
Article Snippet: For cross-pathway validation with SAR408701 (tusamitamab ravtansine), we thankfully acknowledge the provision of data from the ADC development at Sanofi, which are not publicly available, though.
Techniques: Biomarker Discovery, Drug discovery, In Vitro, Cell Culture, In Vivo